Sinopharm Signs MOU to In-License Cancer Treatment from Provectus

Sinopharm (China National Pharmaceutical Group) has signed a Memorandum of Understanding with Provectus Biopharma, a US clinical-stage drug company, to in-license China rights for Provectus's lead drug candidate: PV-10, an immunotherapy aimed at cancer. If the two entities reach a final agreement, Provectus will manufacture PV-10 in the US, and Sinopharm A-THINK will distribute the drug in China. Provectus expects the deal to contain upfront, milestone and royalty payments. More details.... Stock Symbol: (NYSE: PVCT) Share this with colleagues: // //